Ninety One’s Gilead Sciences GILD Stock Holding History

Ninety One’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-380	Closed	-$27K	–	82
2016 Q4	$27K	Sell	380 -10,974	-97%	-$816K	0.02%	79
2016 Q3	$897K	Buy	11,354 +11,049	+3,623%	+$898K	0.57%	34
2016 Q2	$25K	Buy	+305	New	+$27.1K	0.02%	63

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Ninety One's GILD Position: Q1 2017 in Review

Ninety One sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 380 shares — an estimated $27K sold.

Ninety One first reported a position in GILD in Q2 2016 and held it in 3 quarters. The position peaked at $897K in Q3 2016. 1,525 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

Ninety One reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
Ninety One sold 380 Gilead Sciences shares in Q1 2017, an estimated $27K.
Ninety One first reported a position in Gilead Sciences in Q2 2016 and held it in 3 quarters.
Ninety One's Gilead Sciences position peaked at $897K in Q3 2016.
1,525 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on Ninety One's 13F filing for Q1 2017, filed 12 May 2017.